Driving innovation in biopharmaceutical cell line engineering with transcriptomics

Selecting the right clone is one of the most consequential decisions in biological manufacturing — and one of the hardest to get right with phenotypic data alone. Yield, product quality, and long-term process consistency all trace back to what happens at the molecular level inside your cells.

RNA sequencing (RNA-seq) is changing how development teams approach that challenge. By delivering a genome-wide view of gene expression, it adds a layer of molecular evidence that explains why clones behave differently — and flags instability before it shows up in your titer or quality data.

In this white paper, you'll learn:

• Where RNA-seq fits within modern cell line development workflows
• What transcriptomic data can — and can't — tell you at each stage, from clone selection to stability studies
• How to generate decision-grade data that accelerates development timelines
• The transcriptional signatures that distinguish high-performing, stable clones

Whether you're scaling your CLD workflow or looking to reduce late-stage attrition, this guide offers practical, actionable insights into applying next-generation sequencing.

Download the full white paper to explore the science behind smarter clone selection.

For research use only. Not for use in diagnostic procedures.